United Therapeutics Corp. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,240 shares of the business’s stock in a transaction that occurred on Thursday, November 10th. The stock was sold at an average price of $129.82, for a total transaction of $160,976.80. Following the completion of the transaction, the chief executive officer now owns 1,380 shares of the company’s stock, valued at $179,151.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

United Therapeutics Corp. (NASDAQ:UTHR) opened at 134.35 on Tuesday. The firm has a 50-day moving average of $119.28 and a 200-day moving average of $116.82. The company has a market capitalization of $5.70 billion, a P/E ratio of 9.09 and a beta of 1.39. United Therapeutics Corp. has a 52 week low of $97.52 and a 52 week high of $164.04.

United Therapeutics Corp. (NASDAQ:UTHR) last posted its quarterly earnings results on Thursday, October 27th. The biotechnology company reported $4.36 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.38 by $0.98. The firm had revenue of $408.20 million for the quarter, compared to the consensus estimate of $400.58 million. United Therapeutics Corp. had a net margin of 44.40% and a return on equity of 41.78%. The company’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same period last year, the firm posted $3.55 earnings per share. Analysts anticipate that United Therapeutics Corp. will post $16.38 EPS for the current fiscal year.

Insider Buying and Selling by Quarter for United Therapeutics Corp. (NASDAQ:UTHR)

Several analysts have recently issued reports on the stock. Wedbush restated an “outperform” rating and set a $229.00 target price on shares of United Therapeutics Corp. in a research report on Friday, November 4th. Cowen and Company restated a “buy” rating and set a $144.00 target price on shares of United Therapeutics Corp. in a research report on Friday, September 23rd. Zacks Investment Research upgraded shares of United Therapeutics Corp. from a “hold” rating to a “buy” rating and set a $126.00 target price on the stock in a research report on Tuesday, July 26th. Ladenburg Thalmann upgraded shares of United Therapeutics Corp. from a “neutral” rating to a “buy” rating and upped their target price for the company from $128.00 to $138.00 in a research report on Friday, October 28th. Finally, JPMorgan Chase & Co. decreased their target price on shares of United Therapeutics Corp. from $145.00 to $129.00 and set a “neutral” rating on the stock in a research report on Friday, July 29th. Eight analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $137.17.

Institutional investors have recently bought and sold shares of the company. Fisher Asset Management LLC increased its position in United Therapeutics Corp. by 1.0% in the third quarter. Fisher Asset Management LLC now owns 3,124 shares of the biotechnology company’s stock valued at $369,000 after buying an additional 32 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in United Therapeutics Corp. by 0.6% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,373 shares of the biotechnology company’s stock valued at $753,000 after buying an additional 35 shares in the last quarter. Ifrah Financial Services Inc. increased its position in United Therapeutics Corp. by 0.8% in the second quarter. Ifrah Financial Services Inc. now owns 4,642 shares of the biotechnology company’s stock valued at $492,000 after buying an additional 39 shares in the last quarter. Sumitomo Mitsui Asset Management Company LTD increased its position in United Therapeutics Corp. by 1.6% in the second quarter. Sumitomo Mitsui Asset Management Company LTD now owns 3,194 shares of the biotechnology company’s stock valued at $338,000 after buying an additional 50 shares in the last quarter. Finally, First Citizens Bank & Trust Co. increased its position in United Therapeutics Corp. by 1.4% in the third quarter. First Citizens Bank & Trust Co. now owns 3,684 shares of the biotechnology company’s stock valued at $435,000 after buying an additional 50 shares in the last quarter.

United Therapeutics Corp. Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb).

5 Day Chart for NASDAQ:UTHR

Receive News & Stock Ratings for United Therapeutics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corp. and related stocks with our FREE daily email newsletter.